David Wald
Clinical trials sponsored by David Wald, explained in plain language.
-
Donor immune cells get a boost in new cancer trial
Disease control TerminatedThis early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Quick-Made cancer fighter put on hold: new CAR-T study withdrawn
Disease control TerminatedThis study aimed to test a new type of CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that had returned or stopped responding to treatment. The therapy was made from a simple blood draw and took less time to produce than standard CAR-T cells. However, the…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Speedy new cell therapy shows promise for tough lymphoma
Disease control OngoingThis study tests a new, fast-made CAR-T cell therapy (UF-KURE19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose in 21 adults. Researchers also look at how well the therapy shri…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC